Pfizer is working to find out more about a report that a health worker in Alaska suffered an allergic reaction to its vaccine Wednesday.
“We don’t yet have all the details of the report from Alaska about a potential serious allergic reactions but are actively working with local health authorities to assess,” a Pfizer spokesperson told CNN.
“We will closely monitor all reports suggestive of serious allergic reactions following vaccination and update labeling language if needed,” she added. “The prescribing information has a clear warning/precaution that appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.”
When British health authorities rolled out the vaccine there earlier this month, at least two recipients had allergic reactions but they recovered quickly. The New York Times first reported that a health care worker in Alaska suffered a reaction.
“Participants in our Phase 3 trial were excluded if they had a history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the investigational vaccine,” the Pfizer spokesperson told CNN.
“Overall, there were no safety signals of concern identified in our clinical trials, including no signal of serious allergic reactions associated with vaccine. However, reports of adverse events outside of clinical studies are a very important component to our pharmacovigilance activities and we will review all available information on this case and all reports of adverse events following vaccination," she added.